Cancer News and Research

Latest Cancer News and Research

bioMD (BOD) announces new MD, new Chairman and Board

bioMD Limited (ASX:BOD), a company with assets in regenerative tissue engineering technologies today announced the appointment of a new Chairman, a new MD and other changes to its Board. This follows shareholder approval for the acquisition of Allied Medical Ltd., a company that specialises in the sales, distribution and commercialisation of medical technologies.

20 Jun 2011

Contaminated cocaine may lead to public health epidemic

Doctors warned of a potential public health epidemic in a recent report on patients in Los Angeles and New York who developed serious skin reactions after smoking or snorting cocaine believed to be contaminated with a veterinary medication drug dealers are using to dilute, or "cut," up to 70% of the cocaine in the U.S.

20 Jun 2011

Photocure launches Photodynamic Cosmetic for improving skin appearance

Photocure, the world leader in photodynamic technology today announced the commercial launch of Allumera in the US, the first Photodynamic Cosmetic specifically formulated to improve the overall appearance of skin, reduce outward signs of aging and minimize the appearance of pores with minimal downtime and results that last.

20 Jun 2011

Genetic Technologies introduces BREVAGen genetic test for assessing non-familial breast cancer risk

Genetic Technologies Limited, through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen genetic test for assessing non-familial breast cancer risk.

20 Jun 2011

Panacea Global announces name change

Panacea Global Inc.,, a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.

20 Jun 2011

Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder

Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6).

20 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

AARP, Philadelphia Department of Recreation to host outdoor Health and Wellness event

AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.

20 Jun 2011

Endo Pharmaceuticals, Jubilant achieve milestone in cancer drug development program

Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals, of Chadds Ford, Pa, U.S.A., announced today that they have achieved a late stage discovery milestone in their joint program focused on cancer.

20 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Patients who receive poorly co-ordinated care more likely to report medication, treatment errors

Patients who received poorly co-ordinated care or were unable to afford basic medical costs were much more likely to report medication, treatment or care errors, according to an international study published in the July issue of IJCP, the International Journal of Clinical Practice.

20 Jun 2011

Researchers identify nine blood proteins that alter with age

Loss of muscle mass is not only associated with disease, such as HIV and cancer, but also with the normal aging process. Anabolic steroids are sometimes used to reverse loss of lean muscle tissue but they can have unwanted side effects.

20 Jun 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Novel vaccine approach for prostate cancer

Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011